Sugi Predict

Sugi Predict / Targets / RAD23B

RAD23B

UV excision repair protein RAD23 homolog B · P54727 · RAD23B on Sugi Atlas →

0 patent compounds predicted against RAD23B, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to RAD23B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations PHASE2COMPLETED
BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy PHASE2COMPLETED
Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor PHASE1/PHASE2NOT_YET_RECRUITING
Olaparib in Patients With HRD Malignant Mesothelioma PHASE2RECRUITING
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) PHASE1/PHASE2NOT_YET_RECRUITING
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer PHASE1/PHASE2COMPLETED
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers PHASE1/PHASE2COMPLETED
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer PHASE2ACTIVE_NOT_RECRUITING
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies PHASE1/PHASE2RECRUITING
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma PHASE2SUSPENDED
Phase II ABT-888 With Cyclophosphamide PHASE2COMPLETED
A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations PHASE2RECRUITING
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas PHASE1COMPLETED
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC EARLY_PHASE1RECRUITING
Better Delineation of CDK13 Related Phenotype and Epigenetic Signature. nanUNKNOWN
Expression of TET1 Gene in Acute Leukaemia nanUNKNOWN
Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581 nanCOMPLETED
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients nanCOMPLETED
Genetics of Prostate Cancer in Young Patients nanCOMPLETED
Prognostic Biomarkers in Patients With Urothelial Carcinoma nanCOMPLETED
Application of Genetic Polymorphisms of DNA Repair in The Prediction of Prostate Cancer Susceptibility and Its Clinical Outcome nanUNKNOWN
Telomere Repair Gene Mutation in Inflammatory Bowel Disease nanCOMPLETED
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1 nanRECRUITING
Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base nanRECRUITING
Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews nanCOMPLETED
Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a RAD23B binder may also engage these)

ProteinNameSimilarity
Q29RK4 — 1.000 Q29RK4 →
Q4KMA2 — 0.997 Q4KMA2 →
P54728 — 0.997 P54728 →
Q84L32 — 0.990 Q84L32 →
A3KMV2 — 0.990 A3KMV2 →
O74803 — 0.989 O74803 →
P54725 — 0.987 P54725 →
Q40742 — 0.987 Q40742 →
Q84L33 — 0.987 Q84L33 →
P54726 — 0.984 P54726 →
Q84L31 — 0.982 Q84L31 →
Q54LV1 — 0.982 Q54LV1 →
Q84L30 — 0.981 Q84L30 →
P32628 — 0.979 P32628 →
P48510 — 0.970 P48510 →
Q6QN10 — 0.968 Q6QN10 →
Q10169 — 0.968 Q10169 →
Q0U3Y6 — 0.968 Q0U3Y6 →
Q7K2G1 — 0.968 Q7K2G1 →
Q2KIS3 — 0.968 Q2KIS3 →
Q754R2 — 0.968 Q754R2 →
Q2USD7 — 0.967 Q2USD7 →
Q96S82 — 0.967 Q96S82 →
Q99NB8 — 0.966 Q99NB8 →
Q7S906 — 0.966 Q7S906 →
Q0CJ13 — 0.966 Q0CJ13 →
Q5XIR9 — 0.966 Q5XIR9 →
O82143 — 0.966 O82143 →
O13797 — 0.966 O13797 →
Q2H085 — 0.966 Q2H085 →